is xigduo a glp-1 Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature Battle of GLP-1 delivery technologies

Historically, no, but qualifying Medicare beneficiaries can get coverage for Wegovy from July 1, 2026, until December 31, 2027, via the new Medicare GLP-1 Bridge program

I know what it takes to be the best," Williams told People this week

Adherence to Therapy: Only 32% of GLP-1 users remained on therapy at the end of year one, dropping to 15% by year two

It is important to note that individual responses vary, and outcomes depend on dosage titration, baseline metabolic status, and adherence to clinical protocols

Unclear weight loss results

See our full semaglutide versus tirzepatide comparison for additional context on the incretin therapy landscape